Revenue during the quarter grew 4.40 percent to $26.28 million from $25.18 million in the previous year period. Gross margin for the quarter expanded 134 basis points over the previous year period to 45.96 percent. Total expenses were 54.04 percent of quarterly revenues, down from 55.38 percent for the same period last year. This has led to an improvement of 134 basis points in operating margin to 45.96 percent.

Adjusted EBITDA for the quarter stood at negative $0.57 million compared to negative $1.21 million in the prior year second quarter. At the same time, adjusted EBITDA margin stood at negative 2.18 percent for the quarter compared to negative 4.80 percent in the last year period.

Barry Weiner, president, Comments "The year has gotten off to a good start, and we expect to see the year progress nicely as we continue to complete development and file for approval of additional proprietary low cost, high performance molecular diagnostic products designed to capitalize on reimbursement pressures facing diagnostic labs. Our strategic focus is paying off, notably at the Clinical Labs, where our molecular diagnostics services are increasing and our extensive and growing women's health diagnostic services is experiencing increased usage. As we add to our product line-up in this field, we are providing cost savings that can ensue from our growing line of high performing competitive cost products. We are increasing marketing efforts to we expand into the national market."